MV.Health

MV.Health is a London medical-device company building clinically validated products for sexual and pelvic health, a category that has historically attracted little serious investment despite affecting most adults at some point in their lives. The business was founded in 2014 as MysteryVibe and rebranded as MV.Health to reflect a sharper clinical positioning.

Its devices use targeted, adaptive vibration to address conditions including genito-pelvic pain, arousal disorder, erectile dysfunction, vaginal dryness, and prostatitis. The products are FDA Class II-cleared, FSA/HSA eligible, and supported by 15 peer-reviewed studies — including a 2025 Nature paper on psychogenic erectile dysfunction reporting IIEF-5 scores rising from 14.4 to 22.3.

The company has improved outcomes for over 200,000 users across 75-plus countries and won more than 60 international design awards including Red Dot, iF Design, and Design Week. The clinical leadership is headed by Chief Medical Officer Prokar Dasgupta, Professor of Surgery at King's College London, and the laboratory has been described in The Guardian as the only UK facility conducting vibrator research and development.